ResMed stock
RMDNYSEResMed Inc., HealthcareISIN US7611521078
84Score 84 out of 100, Strong
Price and trend
72 / 100
Price history
−5.5% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 6.5% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 38).
The price is 14% below its 52-week high. Largest decline in 20 years: 55% (September 2021 to October 2023).
Chart figures for advanced users
- SMA 50$231.79
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$224.05
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)38
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$182.82
- The lowest closing price of the last twelve months.
- Resistance$275.96
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- ResMed Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $33.55B, is number 6 of 44 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $5.65B (up 9.9% year on year) and earnings of $1.52B (up 8.8%).
- For fiscal 2027, analysts expect on average revenue of $5.83B (up 3.1%) and adjusted earnings per share of $12.14 (up 8.7%).
Show more
- MEQIRI Score 84 out of 100 (Strong): rank 6 of 714 in Healthcare, median 53.
- The P/E is 21.5 (Medical (Instruments & Supplies) median 34.8, own median of recent years 37.5).
- Our model puts fair value at $337.84, with the price 29% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 26.1% a year since 2021.Growth 88
- High marginNet margin 27.8% over the last 12 months, Medical (Instruments & Supplies) median 5.9%.Profitability 95
- Earnings turn into cashFree cash flow 179% of earnings over the last 12 months.Fundamentals 100
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are fundamentals and profitability.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 9 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- high growth grade (crashed more often in the backtest)
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $259.87 and expensive above $482.62 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $289.41 (cash-flow model) and $386.26 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $313.30, at 7.8% it would be $374.68.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 9% on the twelve months before. Revenue has grown solidly since 2007, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 61%, operating 34%, net 27%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 28 Jan 2027in 77 days
- Last reported
- 29 Oct 2026EPS reported $2.91 (expected $2.69)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $12.14+0.3%
- Revenue
- $5.83B+0.3%
- Earnings per share
- $13.25−0.4%
- Revenue
- $6.19B+0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −5.4%Fiscal 2027 guidance is EPS of $12 to $12.25, up about 7% to 10%, with a slight increase in operating margin.
“For fiscal year 2027, we expect year over year revenue growth on this basis to be in the range of 5% to 7%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q4 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $8.63M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Farrell Michael J.Sale
9 Nov 2026, Chairman and CEO
- Shares
- 4,993
- Price
- $235.35
- Value
- $1.18M
- Rider Michael JSale
23 Oct 2026, Global General Counsel
- Shares
- 400
- Price
- $255.00
- Value
- $102,000
- Farrell Michael J.Sale
7 Oct 2026, Chairman and CEO
- Shares
- 4,991
- Price
- $226.33
- Value
- $1.13M
Show 6 more
- Farrell Michael J.Sale
8 Sept 2026, Chairman and CEO
- Shares
- 4,991
- Price
- $222.44
- Value
- $1.11M
- Farrell Peter CSale
2 Sept 2026, Board
- Shares
- 970
- Price
- $234.73
- Value
- $227,688
- Farrell Michael J.Sale
7 Aug 2026, Chairman and CEO
- Shares
- 4,991
- Price
- $205.69
- Value
- $1.03M
- Farrell Peter CSale
5 Aug 2026, Board
- Shares
- 8,000
- Price
- $225.00
- Value
- $1.8M
- Farrell Michael J.Sale
7 Jul 2026, Chairman and CEO
- Shares
- 4,991
- Price
- $218.55
- Value
- $1.09M
- Farrell Michael J.Sale
8 Jun 2026, Chairman and CEO
- Shares
- 4,991
- Price
- $193.96
- Value
- $968,064
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at ResMed
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 84
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- EssilorLuxotticaEL.PA $93.35B62
- Becton, DickinsonBDX $58.43B59
- HOYA7741.T $50.12B76
- MedlineMDLN $37.04B55
- West Pharmaceutical ServicesWST $28.76B78
- Sartorius Stedim BiotechDIM.PA $24.55B58
- Straumann HoldingSTMN.SW $20.49B78
- SartoriusSRT.DE $17.6B59
ETFs that hold ResMed
Held by 103 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Global X Telemedicine & Digital Health UCITS ETFDDOC | 3.39% | 0.68% | €5.31M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.52% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.51% | 0.15% | €3.27B |
Show 5 more
| UBS Factor MSCI USA Quality Screened UCITS ETF USD disUBUT | 0.51% | 0.25% | €1.14B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.50% | 0.12% | €1.34B |
| Deka MSCI USA MC UCITS ETFEL41 | 0.42% | 0.30% | €51.58M |
| iShares MSCI World Health Care Sector Advanced UCITS ETFCBUF | 0.40% | 0.18% | €837.43M |
| Xtrackers MSCI World Health Care UCITS ETF 1CXDWH | 0.38% | 0.25% | €4.18B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 30 Jun 2026
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2023)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.